When a patient is told they have signet ring appendix cancer, that single phrase can mean several different things. Signet ring appendix cancer pathology is more layered than the label suggests, and the document that defines your diagnosis carries details most patients are never walked through.
This post is about the pathology report. It is the single most important document in your file, and a few specific details on it carry significant weight for signet ring patients.
A quick note on terminology. In the medical literature, this disease is often described as signet ring cell appendiceal adenocarcinoma or appendiceal adenocarcinoma with signet ring cell features. This series uses the shorter form for accessibility, but the formal terms are useful when searching the published literature.
What Is Signet Ring Cell Carcinoma (SRCC)?
Signet ring cell carcinoma (SRCC) is a rare and aggressive subtype of appendiceal adenocarcinoma. It is defined by tumor cells that contain large amounts of intracellular mucin, which push the cell’s nucleus to one edge and create a signet-ring appearance under the microscope.
SRCC of the appendix is associated with high-grade disease, diffuse peritoneal spread, more aggressive behavior than other appendiceal subtypes, and worse overall prognosis when signet ring cells make up a higher percentage of the tumor.
What Signet Ring Cells Are
Signet ring cells are named for their appearance under the microscope. Each cell contains a large pool of mucin that pushes the nucleus to one side, making the cell look like a ring with a stone. The mucin is held inside the cell, which is part of what makes signet ring biologically different from other mucinous appendix cancers, where mucin pools outside the cells.
That intracellular mucin is part of why signet ring appendix cancer behaves more aggressively than low-grade mucinous tumors. The cells move differently, spread differently, and respond differently to treatment.
Pure Signet Ring Versus Mixed Histology
This is the distinction most patients are not told about clearly. A tumor can be pure signet ring, where signet ring cells make up the overwhelming majority of the tumor. It can be predominantly signet ring, where signet ring cells make up more than half the tumor but other cell types are also present. Or it can be mixed histology with a signet ring component, where signet ring cells are present but not dominant. This mixed pattern often appears in goblet cell adenocarcinoma and in moderately differentiated mucinous adenocarcinoma, and the report may describe the signet ring portion as a percentage of the total tumor.
These are not the same disease, even though they all get the same words attached to them in casual conversation. The percentage of signet ring cells in the tumor is one of the strongest predictors of outcome that signet ring appendix cancer pathology can give you.
Why the Percentage Matters
The evidence on signet ring percentage is striking. A 2019 study by Munoz-Zuluaga and colleagues at Mercy Medical Center, published in the Annals of Surgical Oncology, looked at 151 patients with high-grade appendix cancer treated with cytoreductive surgery and HIPEC. They separated patients into high-grade mucinous carcinoma peritonei without signet ring cells, and high-grade with signet ring cells. The five-year survival difference between those groups was meaningful, and the presence of signet ring cells changed both prognosis and the rate of positive lymph nodes. (Read the study)
A 2021 analysis by Shamavonian and colleagues at St George Hospital in Australia, published in the European Journal of Surgical Oncology, looked at 255 patients and broke the signet ring group into low count and high count. Median overall survival was 93.8 months without signet ring cells, 58.2 months with a low count, and 23.7 months with a high count. Five-year survival was 60 percent, 35.5 percent, and 10 percent across those same three groups. (Read the study)
The US HIPEC Collaborative, a 12-center database analysis published in 2020, confirmed the pattern in a larger and more diverse population. Of 514 patients undergoing CRS-HIPEC for appendiceal adenocarcinoma, 125 had signet ring features, and overall and recurrence-free survival were significantly worse in that group. (Read the study)
That single number on a pathology report can change how a patient’s case is discussed at tumor board, what treatments are offered, and how aggressively a surveillance plan is built. If your report does not include the percentage, that is worth asking about.
Why a Second Pathology Opinion Matters
Signet ring appendix cancer is rare enough that many community pathologists may see only a handful of cases in their career. The diagnosis of signet ring, especially in mixed histology tumors, can be subjective at the margins. Some institutions are more rigorous than others about quantifying the signet ring component and distinguishing it from goblet cell features.
A second pathology review at a high-volume peritoneal surface malignancy center is one of the most useful steps a signet ring appendix cancer pathology patient can take. Centers that see a high volume of appendix cancer have pathologists who specialize in this disease, and a second read can change the diagnosis, change the percentage assessment, or confirm the original report with much higher confidence. Appendicure maintains a directory of specialists at high-volume centers.
This is less about distrusting your local pathologist and more about recognizing that rare cancers are read more accurately by pathologists who see them often.
What to Look For on Your Report
A few specific items on a signet ring appendix cancer pathology report carry weight. The percentage of signet ring cells in the tumor matters most. So does whether the tumor is described as pure, predominantly signet ring, or mixed with another histology. The grade is also critical. Most signet ring tumors fall into the higher grade categories, but not all, and the three-tier WHO grading system distinguishes G1, G2, and G3 in ways that matter for treatment planning.
You also want to look at the status of the margins, lymph nodes, and any peritoneal involvement. Lymph node status is particularly important in signet ring cancer because positive nodes are more common in this subtype and meaningfully change prognosis.
Finally, check whether the tumor expresses certain markers such as MUC2, CK20, and CDX2. These help confirm the appendiceal origin and rule out metastasis from a different primary site, which is a real consideration when signet ring features are present.
These details matter because the 2025 Peritoneal Surface Malignancies Consortium consensus guidelines, often referred to as the Godfrey guidelines after their first author, treat appendiceal cancer as biologically distinct from colorectal cancer and use specific pathology features to guide decisions about surgery, surveillance, and systemic therapy. They represent one of the first comprehensive appendiceal-specific consensus frameworks, which is a meaningful shift for a disease that was treated as a footnote to colorectal cancer for decades.
If any of these are missing or unclear in your report, those are reasonable questions to bring to your care team.
What This Means for Next Steps
Understanding your signet ring appendix cancer pathology report does not change your diagnosis, but it changes what you can do with it. Patients who know the specific characteristics of their tumor are better positioned to ask informed questions, to seek out specialists with relevant experience, and to evaluate treatment recommendations against what the published evidence actually says for their particular situation.
Part 3 in this series covers the broader research framework now organizing around appendix cancer, why outcomes are still so hard to predict, and what patients can do to be part of changing that.
Catch up on the series:
Part 1: What the Evidence Says About Treatment
Part 3: Why the Picture Is Still Incomplete, and How to Be Part of Completing It
Related Guides on APPENDICURE
For a deeper look at the topics in this article:
Types of Appendix Cancer, a plain-language guide to LAMN, HAMN, appendiceal adenocarcinoma, signet ring cell carcinoma, goblet cell adenocarcinoma, neuroendocrine tumors, and pseudomyxoma peritonei.
Diagnosis and Treatment, how appendix cancer is diagnosed, what treatments exist (CRS, HIPEC, systemic chemo, targeted therapy, clinical trials), and what to ask your doctor.
If you would like to be part of the data that drives better research and care for rare appendix cancers, you can join the Appendicure Patient Data Registry (United States or International).
References
Munoz-Zuluaga C, et al. Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2019.
Shamavonian R, et al. Impact of signet ring cells on overall survival in peritoneal disseminated appendix cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. European Journal of Surgical Oncology, 2021.
Levinsky NC, et al. Should we be doing cytoreductive surgery with HIPEC for signet ring cell appendiceal adenocarcinoma? A study from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2020.
Godfrey EL, et al; Peritoneal Surface Malignancies Consortium Group. Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 1: Appendiceal Tumors Without Peritoneal Involvement. Cancer, 2025. doi:10.1002/cncr.35867
Godfrey EL, et al; Peritoneal Surface Malignancies Consortium Group. Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 2: Appendiceal Tumors With Peritoneal Involvement. Cancer, 2025. doi:10.1002/cncr.35874
Leave a Reply